Effects of linezolid and vancomycin on treatment of ventilator-associated pneumonia caused by meticillin-resistant Staphylococcus aureus

OBJECTIVE To explore the efficacy and safety of linezolid and vancomycin in the treatment of ventilator-associated pneumonia(VAP) caused by meticillin-resistant Staphylococcus aureus(MRSA) so as to guide the clinical diagnosis and treatment.METHODS A total of 68 cases of patients with VAP caused by MRSA were randomly divided into the linezolid group(n=34) and the vancomycin group(n=34).All the treatment courses were 7-14 days.The clinical effect,bacterial clearance rate,inflammatory reaction and side effect were observed and compared.RESULTS The bacterial clearance rate and the total effective rate of the linezolid group were respectively 73.5% and 64.7%,significantly higher than 55.9% and 44.1% of the vancomycin group,the difference was statistically significant(P0.05).The levels of white blood cell,C-reactive protein and procalcitonin in both groups were significantly decreased compared with those before the treatment(P0.05),while those indicators were decreased more remarkably in the linezolid group than in the vancomycin group,the difference was statistically significant(P0.05).The incidence rate of the adverse reaction was 8.8% in the linezolid group and 14.7% in the vancomycin group,the difference was not statistically significant.CONCLUSION Linezolid is more effective than vancomycin in the treatment of VAP caused by MRSA,it can remarkably raise the bacterial clearance rate and reduce the pulmonary inflammatory reactions,with less adverse reactions caused.